Cargando…
Profile of tocilizumab and its potential in the treatment of giant cell arteritis
Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this gro...
Autores principales: | Mollan, Susan Patricia, Horsburgh, John, Dasgupta, Bhaskar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790065/ https://www.ncbi.nlm.nih.gov/pubmed/29416384 http://dx.doi.org/10.2147/EB.S127812 |
Ejemplares similares
-
Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013) -
Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016) -
Giant cell arteritis: reviewing the advancing diagnostics and management
por: Bilton, Edward J., et al.
Publicado: (2023) -
Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022) -
Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022)